| Ytd | -29.04% | |
| 1y | 171.30% |
| Open | 48.17 | Prev Close | 49.35 | Low | 48.17 | High | 49.22 | Mkt Cap | 2.84B |
| Vol | 11.00 | Avg Vol | 797.91K | EPS | -1.57 | P/E | -31.43 | Forward P/E | -27.60 |
| Beta | -1.50 | Short Ratio | 6.71 | Inst. Own | 96.05% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-06 | 50-d Avg | 44.30 | 200-d Avg | 51.14 | 1yr Est | 104.59 |
GPCR News
As millions take GLP-1 drugs, packaged food giants face declining volumes while protein brands and s
Top Wall Street analysts changed outlook on top names. See full list of rating changes on analyst ra
HC Wainwright & Co. analyst Ananda Ghosh maintains Structure Therapeutics (NASDAQ:GPCR) with
Aleniglipron is an oral, small-molecule glucagon-like peptide-1 receptor agonist (GLP1-RA) in develo
Structure Therapeutics (NASDAQ:GPCR) reported quarterly losses of $(0.35) per share which met the an
Canaccord Genuity analyst Edward Nash initiates coverage on Structure Therapeutics (NASDAQ:GPCR)
Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company develo
Structure Therapeutics shares rose, likely driven by FDA approval of a competing obesity treatment,
HC Wainwright & Co. analyst Ananda Ghosh maintains Structure Therapeutics (NASDAQ:GPCR) with
https://www.barrons.com/articles/structure-therapeutics-weight-loss-pill-trial-stock-93dba470
Structure Therapeutics' Phase 2 ACCESS II trial shows up to 16.3% placebo-adjusted weight loss f
HC Wainwright & Co. analyst Ananda Ghosh maintains Structure Therapeutics (NASDAQ:GPCR) with
Citizens analyst Jonathan Wolleben maintains Structure Therapeutics (NASDAQ:GPCR) with a Market O
Structure Therapeutics (NASDAQ:GPCR) reported quarterly losses of $(0.36) per share which beat the a
https://www.axios.com/pro/biotech-deals/2026/01/30/structure-therapeutics-pharmas-next-buyout-glp1
